1980•PubMedRequires access

[Quality of roentgenological visualization and tolerance of various intravenous cholegraphic contrast media (author's transl)].

Patricia Tischendorf

Open publisher page 1 citations

Abstract

The recently introduced intravenous cholegraphic contrast media produce a greater diagnostic yield in radiological routine thanks to improved roentgenological contrasting. Whereas the percentage share of roentgenologically clearly assessable cases is about 75 % when using Biligrafin, this percentage is much higher with the more recent contrast media, especially Biliscopin, namely, up to 88 %. These new contrast media are also superior in respect of tolerance, since they produce fewer side effects. While side effects must be expected in about 28 % of the cases when injecting Biligrafin, the side effect quota is about 10 % only with Biliscopin or Endomirabil. If the contrast medium is infused instead of injected, the quota of side effect drops to 2.3 % with Biliscopin or 3.9 % with Endomirabil. Slight and medium side effects have definitely decreased with the more recent contrast media. The slower and more continually the contrast medium is administered, the fewer are the side effects observed; this becomes particularly noticeable in the case of long-term infusions. However, the likelihood of severe incidents caused by the contrast medium, remains unchanged at about 1 % of the examined patients, even with the more recently introduced contrast media.

About this research paper

What this paper is about

The recently introduced intravenous cholegraphic contrast media produce a greater diagnostic yield in radiological routine thanks to improved roentgenological contrasting. Whereas the percentage share of roentgenologically clearly assessable cases is about 75 % when using Biligrafin, this percentage is much higher with the more recent contrast media, especially Biliscopin, namely, up to 88 %. These new contrast media are also superior in respect of tolerance, since they produce fewer side effects. While side effects must be expected in about 28 % of the cases when injecting Biligrafin, the side effect quota is about 10 % only with Biliscopin or Endomirabil. If the contrast medium is infused instead of injected, the quota of side effect drops to 2.3 % with Biliscopin or 3.9 % with Endomirabil. Slight and medium side effects have definitely decreased with the more recent contrast media. The slower and more continually the contrast medium is administered, the fewer are the side effects observed; this becomes particularly noticeable in the case of long-term infusions. However, the likelihood of severe incidents caused by the contrast medium, remains unchanged at about 1 % of the examined patients, even with the more recently introduced contrast media.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The recently introduced intravenous cholegraphic contrast media produce a greater diagnostic yield in radiological routine thanks to improved roentgenological contrasting. Whereas the percentage share of roentgenologically clearly assessable cases is about 75 % when using Biligrafin, this percentage is much higher with the more recent contrast media, especially Biliscopin, namely, up to 88 %. These new contrast media are also superior in respect of tolerance, since they produce fewer side effects. While side effects must be expected in about 28 % of the cases when injecting Biligrafin, the side effect quota is about 10 % only with Biliscopin or Endomirabil. If the contrast medium is infused instead of injected, the quota of side effect drops to 2.3 % with Biliscopin or 3.9 % with Endomirabil. Slight and medium side effects have definitely decreased with the more recent contrast media. The slower and more continually the contrast medium is administered, the fewer are the side effects observed; this becomes particularly noticeable in the case of long-term infusions. However, the likelihood of severe incidents caused by the contrast medium, remains unchanged at about 1 % of the examined patients, even with the more recently introduced contrast media.

Key concepts: Contrast (vision), Contrast medium, Intravenous contrast, Medium term, Medicine, Side effect (computer science), Yield (engineering), Surgery

Related papers

Back to paper searchBrowse research topicsOriginal source
[Quality of roentgenological visualization and tolerance of various intravenous cholegraphic contrast media (author's transl)]. — Research Paper | ScholarLens